Labropharm (DDSS) and Paladin (PLB.TO) Announce Expansion of Commercial Relationship
Yesterday, pharmaceutical companies Labropharm and Paladin Labs made the announcement that they are expanding their current relationship with several licensing and distribution deals, wherein Paladin will distribute two of Labropharm's products. Firstly, Paladin has been granted the right to market and sell INTELLILAB-based twice-daily oxycondone-acetaminophen in Canada, subject to Labropharm's co-promote right in the country. Both companies will collaborate on a development of the product, with both companies contributing to funding development as it relates to meeting Canadian regulatory approval. Paladin also has the right of first opportunity in Canada on a second INTELLILAB-based pain medication for Canadian distribution. This…